Novotech White Papers

  1. The Biotech Landscape: Opportunities In China And The Path To USFDA Approval 11/7/2022

    In this white paper, learn why western biopharma companies should take advantage of China’s revamped regulatory framework.

  2. Next Generation Sequencing In The Asia Pacific: The Availability & Reimbursement Landscape 9/22/2022

    Next generation sequencing (NGS) refers to a technology that detects genomic variation that is present at birth or emerges later in life. This report describes the availability of NGS in a selection of locations.

  3. How Biotechs Are Using DCT Technology To Conduct Trials In The APAC Region 9/22/2022

    In this white paper, gain insight into how the Asia Pacific region, with its rapid growth of clinical trials, presents a great opportunity for conducting clinical research and has become the preferred destination for DCTs.

  4. The Immuno-Oncology Clinical Trial Landscape In The Asia Pacific 9/22/2022

    Learn how the Asia Pacific has shown significant increase in Immuno-oncology (IO) trials between 2017 and 2021 and contributes to about 35% of clinical development in IO globally. 

  5. Clinical Development Strategies For Western Biotech Companies In China 9/22/2022

    Delve into how China is now more aligned with international standards, enabling biotech firms to streamline processes and timelines, which has significantly recharged biotech innovation.

  6. Evolution Of Clinical Trials In The Asia Pacific Region 9/22/2022

    With changing global clinical trials landscape, explore how APAC is emerging as the hot spot for conducting clinical trials, especially in China.